Skip to content. | Skip to navigation

Personal tools

Karen Gelmon

Peer-Reviewed Papers


Peer-Reviewed Papers | Publications


1.      Campbell KL, Lane K, Martin AD, Gelmon KA, McKenzie DC. Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer. Cancer Nurs. 30(2):95-100. (2007).

2.      Gelmon K. Prescribing extended adjuvant letrozole. Breast. . (2007).

3.      Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol. 18(1):45-51. Epub 2006 Oct 9. (2007).

4.      Mackey John and Gelmon Karen. Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications. Current Opinion in Oncology. 19(supp 1):S9-18. (2007).

5.      Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 13(4):1238-45. (2007).

6.      Pansegrau GK, Grant DR, Norris B, Gelmon KA. Trastuzumab-associated peripheral vascular toxicity. J Clin Oncol. 25(11):1438-40. (2007).

7.      Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369(9555):29-36. (2007).



8.      Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 24(36):5637-44. Epub 2006 Nov 20. (2006).

9.      Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 24(18):2773-8. Epub 2006 May 8. (2006).

10.  Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist. 11 Suppl 1:42-51. (2006).

11.  Kennecke HF, Ellard S, O'Reilly S, Gelmon KA. New guidelines for treatment of early hormone positive breast cancer with tamoxifenand aromatase inhibitors. BCMJ. 48:121-6 (2006).

12.  Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 24(30):4888-94. Epub 2006 Oct 2. (2006).

13.  Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer. 7(3):254-61. (2006).

14.  Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).

15.  Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol. 19(1):69-74. (2006).

16.  Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).



17.  Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, Gelmon KA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 23(4):311-5. (2005).

18.  Chia S, Bryce C, Gelmon K. The 2000 EBCTCG overview: a widening gap. Lancet. 365(9472):1665-6. (2005).

19.  Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Charpentier D, Chi K, Powers J, Walsh W, Seymour L. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130. Invest New Drugs. 23(5):445-53. (2005).

20.  Martin M, Pienkowski MD, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C for the Breast International Research Group 001 Investigators . Adjuvant Docetaxel for Node Positive Breast Cancer. NEJM. 352:2302-13. (2005).

21.  McCullum M, Bottoroff JL, Balneaves LG, Davison BJ, Esplen MJ, Kim-Sing C, Gelmon KA, Lamb S, Kuusk U, Kieffer S. Tough choices: A preliminary evaluation of an intervention to support decision making about prophylactic mastectomy. Nursing and Health Sciences. 7:144-5 (2005).

22.  Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 23(12):2716-25. (2005).

23.  Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 97(2):116-26. (2005).

24.  Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, McLeod D, Pritchard K, Provencher L, Verma S. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 6(11):886-98. (2005).

25.  Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).

26.  Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103(9):1770-7. (2005).



27.  Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Gelmon K, Chia S, Hayes M. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol. 17(6):690-5. (2004).

28.  Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res. 2(11):606-19. (2004).

29.  Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, Onetto N, Eisenhauer E. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs. 22(3):263-75. (2004).

30.  Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, Bell R, Heinrich B, Grenier D, Dias R. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 5(1):52-8; discussion 59-62. (2004).

31.  Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. Ann Oncol. 15(7):1115-22. (2004).

32.  MacKenzie MJ, Hirte HW, Siu LL, Gelmon K, Ptaszynski M, Fisher B, Eisenhauer E. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol. 15(4):665-70. (2004).

33.  Pansegrau GK, Gelmon KA. Lymph-node-negative oestrogen-receptor-positive breast cancer. Lancet. 364(9437):820-1. (2004).

34.  Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol. 22(2):269-76. (2004).

35.  Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancy J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K, Marx GM, Rutovitz JJ. Phase III study of N, N-diethyl-2 - (4-(Phenylmethyl) Phenoxyl) Etnanamine (BMS-2173802-01) combined with doxorubicin versus doxorubicin alone in metastatic /recurrent breast cancer: National Cancer Institute of Canada Clinical Trial Group Study MA-19. Women's Oncology Review. 4(2):133-4. (2004).

36.  Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, Roskelley CD. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res. 64(15):5068-73. (2004).

37.  Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res. 10(7):2512-24. (2004).

38.  Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol Ther. 3(2):197-204. Epub 2004 Feb 1. (2004).



39.  Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs. 21(1):85-97. (2003).

40.  Gelmon KA, Vandenberg TA, Panasci L, Norris B, Crump M, Douglas L, Walsh W, Matthews SJ, Seymour LK. A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129. Ann Oncol. 14(4):543-8. (2003).

41.  Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 21(21):3965-71. Epub 2003 Sep 24. (2003).

42.  Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol. 3(5):261-71. (2003).



43.  De Lemos M. Safety issues of soy phytoestrogens in breast cancer patients. J Clin Oncol. 20(13):3040-1; author reply 3041-2. (2002).

44.  Gelmon K, Olivotto I. The mammography screening debate: time to move on. Lancet. 16; 359(9310):909-19. (2002).

45.  Hanna, W and Gelmon K. Review of the literature on Her2/neu testing and the role of Her2/neu as a prognostic and predictive factor in breast cancer - Update December 2000 to July 2001. Current Oncology. 9 supp 1: S2-S17. (2002).

46.  Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, Hislop TG, Templeton E, Wattie A, Prior JC. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 20(6):1449-55. (2002).



47.  Bebb DG, Warrington PJ, de Jong G, Yu Z, Moffat JA, Skov K, Spacey S, Gelmon K, Glickman BW. Radiation induced apoptosis in ataxia telangiectasia homozygote, heterozygote and normal cells. Mutat Res. 476(1-2):13-20. (2001).

48.  Gelmon, Karen A and Kim Sing Charmaine. Hormone therapy and breast cancer. BCMJ. 43(9):511-6. (2001).

49.  Leyland-Jones B, Arnold A, Gelmon K, Verma S, Ayoub JP, Seidman A, Dias R, Howell J, Rakhit A. Pharmacologic insights into the future of trastuzumab. Ann Oncol. 12 Suppl 1:S43-7. (2001).



50.  Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol. 18(24):4098-108. (2000).



51.  Bebb DG, Yu Z, Chen J, Telatar M, Gelmon K, Phillips N, Gatti RA, Glickman BW. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer. 80(12):1979-81. (1999).

52.  Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 17(10):3038-47. (1999).

53.  Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 91(15):1281-7. (1999).

54.  Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol. 17(2):697-705. (1999).

55.  Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 17(2):478-84. (1999).



56.  Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol. 41(5):347-52. (1998).

57.  Gelmon K, Tolcher A, O'Reilly S, Shenkier T. A phase II study of biweekly paclitaxel in metastatic breast cancer. Annals of Oncology. 9: 1247-9. (1998).

58.  Gelmon KA. The fine points of endpoints. Phase II trials in non small cell lung cancer. Annals of Oncol. 9:1045-6 (1998).

59.  Latreille J, Gelmon KA, Hirsh V, Laberge F, Maksymiuk AW, Shepherd FA, Delorme F, Berille J. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest New Drugs. 16(3):265-70. (1998).

60.  Murray N, Grafton C, Shah A, Gelmon K, Kostashuk E, Brown E, Coppin C, Coldman A, Page R. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol. 16(10):3323-8. (1998).

61.  O'Reilly S, Shenkier T, Allan S, Gelmon K. Therapy for adjuvant systemic non-cancer Canadian Treatment Guidelines for node positive breast cancer. CMJ 158; (3 Supp). 552-64. (1998).

62.  Shepherd FA, Beaulieu R, Gelmon K, Thuot CA, Sawka C, Read S, Singer J. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol. 16(5):1736-42. (1998).

63.  Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 42(6):461-70. (1998).

64.  Westeel V, Murray N, Gelmon K, Shah A, Sheehan F, McKenzie M, Wong F, Morris J, Grafton C, Tsang V, Goddard K, Murphy K, Parsons C, Amy R, Page R. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol. 16(5):1940-7. (1998).



65.  Bebb G, Glickman B, Gelmon K, Gatti R. "AT risk" for breast cancer. Lancet. 349(9068):1784-5. (1997).

66.  Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal. 16(4):675-87. (1997).

67.  Goss PE, Fine S, Gelmon K, Rudinskas L, Ottaway J, Myles J, James K, Paul K, Rodgers A, Pritchard KI. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemother Pharmacol. 41(1):53-60. (1997).

68.  Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H. A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 39(5):1107-11. (1997).

69.  Munk PL, Poon PY, O'Connell JX, Janzen D, Coupland D, Kwong JS, Gelmon K, Worsley D. Osteoblastic metastases from breast carcinoma with false-negative bone scan. Skeletal Radiol. 26(7):434-7. (1997).



70.  Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, Coppin C, Plenderleith IH, Ayers D, McDermott B, Nakashima L, Healey D, Onetto N. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol. 14(4):1185-91. (1996).

71.  Millar JL, Goldstein D, Gelmon KA. Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcoma. Med J Aust. 164(9):539-42. (1996).

72.  Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 14(6):1858-67. (1996).



73.  De Jong G, Gelmon K, Bally M, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res. 15(3):911-6. (1995).



74.  Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, Hirsh V, Eisenhauer E. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 86(4):306-9. (1994).

75.  Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 344(8932):1267-72. (1994).

76.  Gelmon K, Member of Concorde Coordinating Committee. MRC/ANRS randomized double-blind controlled total comparing immediate and deferred zidovidine in asymptomatic HIV infection. Lancet. 343(901):892-8. (1994).

77.  Olivotto IA, Bajdik CD, Plenderleith IH, Coppin CM, Gelmon KA, Jackson SM, Ragaz J, Wilson KS, Worth A. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med. 330(12):805-10. (1994).

78.  Osoba D, Murray N, Gelmon K, Karsai H, Knowling M, Shah A. Phase II Trial of Megesteriol in the supportive care of patients receiving dose intensive chemotherapy. Oncology. 8(3):43-68. (1994).

79.  Osoba D, Murray N, Gelmon K, Karsai H, Knowling M, Shah A, McLaughlin M, Fetherstonhaugh E, Page R, Bowman CA. Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy. Oncology (Williston Park). 8(4):61-5; discussion 65-6, 69. (1994).



80.  Embree L, Gelmon KA, Lohr A, Mayer LD, Coldman AJ, Cullis PR, Palaitis W, Pilkiewicz F, Hudon NJ, Heggie JR, et al.. Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. J Pharm Sci. 82(6):627-34. (1993).

81.  Gregg RW, Kaizer L, Fine S, Gelmon K, Wielgosz G, Eisenhauer E. A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group. Ann Oncol. 4(8):693-4. (1993).

82.  O'Reilly SE, Gelmon KA, Onetto N, Parente J, Rubinger M, Page RA, Plenderleith IH. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. J Clin Oncol. 11(12):2411-6. (1993).

83.  Schechter MT, Craib KJ, Gelmon KA, Montaner JS, Le TN, O'Shaughnessy MV. HIV-1 and the aetiology of AIDS. Lancet. 341(8846):658-9. (1993).



84.  Osoba D, Band PR, Goldie JH, Connors JM, Gelmon K, Knowling MA, Fetherstonhaugh EM. Efficacy of weekly cisplatin-based chemotherapy in recurrent and metastatic head and neck cancer. Ann Oncol. 3 Suppl 3:57-62. (1992).


85.  Montaner JS, Le T, Fanning M, Gelmon K, Tsoukas C, Falutz J, O'Shaughnessy M, Wainberg MA, Ruedy J. The effect of zidovudine on platelet count in HIV-infected individuals. J Acquir Immune Defic Syndr. 3(6):565-70. (1990).



86.  Gelmon K, Weller IV. Randomised placebo controlled trials in HIV infection: to be or not to be? Genitourin Med. 65(3):143-5. (1989).

87.  Price LA, Hill BT, Gelmon KA. Intermittent high-dose zidovudine. Lancet. 2(8665):734. (1989).

88.  Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao XJ, Fanning M, Montaner JS, O'Shaughnessy M, Gelmon K, Tsoukas C, et al.. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 3(7):411-5. (1989).

89.  Wainberg MA, Falutz J, Fanning M, Gill J, Gelmon K, Montaner JS, O'Shaughnessy M, Tsoukas C, Ruedy J. Cessation of zidovudine therapy may lead to increased replication of HIV-1. JAMA. 261(6):865-6. (1989).



Peer-Reviewed Papers | Publications


1.      Bebb G, Glickman B, Gelmon K, Gatti R. Lancet 349:1784-1785 (1997).

2.      Kirkbride P, Gelmon K, Eisenhauer E. et al. J of Rad Biol and Phys, 39. 1107-1111 (1997).


3.      Gelmon KA, O'Reilly SE, Tolcher AW, et al. J Clin Oncol, 14: 1185-1191 (1996).



4.      Gelmon K. The Lancet, 344; 1267-72 (1994).



5.      Embree L, Gelmon KA, Lohri A, Mayer LD et al. J. Pharm Sci, 82:627-634 (1993).

6.      O'Reilly S, Gelmon KA, Onetto N et al. J Clin Oncol 11(12) 1-6 (1993).



7.      Gelmon K, Montaner JS, Fanning M et al. AIDS, 3(9); 555-561 (1989).


Back to Karen Gelmon

Back to Main Page